Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

1.

Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder.

Blum NJ, Jawad AF, Clarke AT, Power TJ.

Dev Med Child Neurol. 2011 Sep;53(9):843-9. doi: 10.1111/j.1469-8749.2011.03944.x. Epub 2011 May 18.

PMID:
21585365
[PubMed - indexed for MEDLINE]
2.

Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):121-31. doi: 10.1089/cap.2010.0047. Epub 2011 Apr 13.

PMID:
21488750
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.

Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK.

J Clin Psychiatry. 2007 Jan;68(1):93-101.

PMID:
17284136
[PubMed - indexed for MEDLINE]
4.

Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.

Pearson DA, Santos CW, Casat CD, Lane DM, Jerger SW, Roache JD, Loveland KA, Lachar D, Faria LP, Payne CD, Cleveland LA.

J Am Acad Child Adolesc Psychiatry. 2004 Jun;43(6):677-85.

PMID:
15167084
[PubMed - indexed for MEDLINE]
5.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
[PubMed - indexed for MEDLINE]
6.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47. Epub 2008 Dec 2.

PMID:
19192455
[PubMed - indexed for MEDLINE]
7.

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

PMID:
18312050
[PubMed - indexed for MEDLINE]
8.

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.

Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.

PMID:
18206857
[PubMed - indexed for MEDLINE]
9.
10.

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.

Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

PMID:
16389216
[PubMed - indexed for MEDLINE]
11.

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.

Fallu A, Richard C, Prinzo R, Binder C.

Curr Med Res Opin. 2006 Dec;22(12):2557-66.

PMID:
17166338
[PubMed - indexed for MEDLINE]
12.

A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits.

Leitner Y, Doniger GM, Barak R, Simon ES, Hausdorff JM.

J Child Neurol. 2007 Mar;22(3):264-76.

PMID:
17621495
[PubMed - indexed for MEDLINE]
13.

The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.

Coghill DR, Rhodes SM, Matthews K.

Biol Psychiatry. 2007 Nov 1;62(9):954-62. Epub 2007 Jun 1.

PMID:
17543895
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
[PubMed - indexed for MEDLINE]
15.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
[PubMed - indexed for MEDLINE]
16.

A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.

Rubio B, Hernández S, Verche E, Martín R, González-Pérez P.

Atten Defic Hyperact Disord. 2011 Mar;3(1):13-20. doi: 10.1007/s12402-010-0035-x. Epub 2010 Oct 21.

PMID:
21432614
[PubMed - indexed for MEDLINE]
17.

Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.

Newcorn JH, Stein MA, Cooper KM.

J Child Adolesc Psychopharmacol. 2010 Jun;20(3):187-96. doi: 10.1089/cap.2009.0102.

PMID:
20578931
[PubMed - indexed for MEDLINE]
18.

Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder.

Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B.

J Am Acad Child Adolesc Psychiatry. 2004 Feb;43(2):191-8.

PMID:
14726726
[PubMed - indexed for MEDLINE]
19.

Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.

Ginsberg Y, Lindefors N.

Br J Psychiatry. 2012 Jan;200(1):68-73. doi: 10.1192/bjp.bp.111.092940. Epub 2011 Nov 10.

PMID:
22075648
[PubMed - indexed for MEDLINE]
Free Article
20.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk